Transient Ischemic Attack
TIA is now defined by the absence of infarction on neuroimaging rather than by the old 24-hour symptom cutoff, and a focal deficit that resolves still carries a high short-term stroke risk that the ABCD2 score, vascular imaging, and cardiac evaluation must be used to stratify and act on urgently.
- Topic reviewThe full article, organized the way the exam asks it.
- ABIM-format MCQsVignettes with an explanation for every wrong answer.
- Key factsThe numbers and thresholds worth memorizing, up front.
- AI tutorMedBrain answers the question you're stuck on.
What this article covers
- Overview
TIA is defined by tissue, not time: a temporary focal neurologic deficit from cerebral ischemia with no infarction on neuroimaging.
- Epidemiology
Stroke risk after TIA follows the rule of 3s: about one-third go on to cerebral infarction, one-third have at least one more TIA, one-third have no further events.
- Risk factors
Age 60 years or older independently raises TIA likelihood and subsequent stroke risk.
- Pathophysiology
Large-artery atherosclerosis (roughly 25%): plaque rupture with artery-to-artery embolism from the extracranial carotid or vertebral arteries or intracranial vessels; transient hypoperfusion or…
- Clinical features
Sudden, focal, negative neurologic symptoms are the hallmark, mirroring the vascular territory: hemiparesis, monocular or homonymous visual field loss, dysarthria, aphasia, unilateral sensory loss.
- Differential diagnosis
Acute ischemic or hemorrhagic stroke: distinguished from TIA only by demonstrable infarction (or hemorrhage) on neuroimaging; a resolved deficit does not exclude an established infarct.
- Diagnosis
TIA is diagnosed when neuroimaging (ideally diffusion-weighted MRI) shows no infarction corresponding to a transient focal deficit; a matching infarct reclassifies the event as stroke.
- Management
First, for high-risk TIA (ABCD2 4 or greater) or minor ischemic stroke (NIHSS 3 or less), start dual antiplatelet therapy within 24 hours of onset and continue for 21 days, then step down to…
- Complications
Recurrent stroke, the central risk of TIA: 4%-10% within 1 year, up to one-third lifetime, concentrated in the first 48 hours to 2 weeks, especially with high-grade ICA stenosis or a high ABCD2 score.
- Prognosis
Recurrence follows the rule of 3s: one-third infarction, one-third at least one further TIA, one-third no additional events.
- Prevention
Primary prevention in asymptomatic carotid stenosis relies on best medical therapy including high-intensity statin therapy, keeping first-stroke risk under about 2% per year; revascularization is not…
Read the whole article
Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.
Related articles
- Ischemic stroke
Ischemic stroke is sudden focal neurologic deficit from arterial occlusion confirmed by infarction on neuroimaging. Diagnosis relies on urgent noncontrast head CT to exclude hemorrhage; treatment is IV alteplase within 4.5 hours and mechanical thrombectomy for large-vessel occlusion within an extended window, followed by antiplatelet therapy and risk-factor control.
- Antiplatelet agents
Antiplatelet agents block platelet activation and aggregation to prevent arterial thrombosis. Aspirin irreversibly inhibits cyclooxygenase-1, and P2Y12 inhibitors such as clopidogrel, ticagrelor, and prasugrel block adenosine diphosphate-driven platelet activation. Aspirin 81 mg daily anchors secondary prevention, and dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor is first-line after acute coronary syndrome or coronary stenting.
- Carotid artery stenosis
Carotid artery stenosis is atherosclerotic narrowing of the extracranial internal carotid artery that raises ischemic stroke risk, graded by percent luminal narrowing on duplex ultrasound. Symptomatic stenosis of at least 50% warrants urgent revascularization; asymptomatic stenosis under 80% is managed with best medical therapy alone, including a high-intensity statin and antiplatelet agent.
- Atrial fibrillation
Atrial fibrillation is a supraventricular tachyarrhythmia with disorganized atrial activation and an irregularly irregular ventricular response, the most common sustained arrhythmia and a major cause of stroke. Diagnosis is by ECG showing no discrete P waves with irregular RR intervals, and management addresses rate or rhythm control, stroke prevention by CHA2DS2-VASc-guided anticoagulation, and the underlying cause.
- Lacunar stroke
Small subcortical infarct, under 1.5 cm, from occlusion of a single penetrating artery, most often caused by hypertensive lipohyalinosis, producing one of five classic pure motor, pure sensory, ataxic hemiparesis, dysarthria-clumsy hand, or mixed sensorimotor syndromes without cortical signs, diagnosed by MRI and managed with the standard acute stroke pathway plus aggressive antiplatelet, statin, and blood pressure secondary prevention.
- Aphasia
Aphasia is an acquired disorder of language production and/or comprehension from a dominant-hemisphere lesion, most commonly acute ischemic stroke; a bedside exam of fluency, comprehension, and repetition localizes the syndrome and drives the emergent stroke workup and thrombolysis/thrombectomy decision.
- Migraine headache
Migraine is a primary episodic headache disorder diagnosed by ICHD-3 clinical criteria (recurrent attacks, 4-72 hours, pulsatile/unilateral pain with nausea or photophobia/phonophobia). First-line acute treatment is an NSAID or oral triptan started early in the attack; prevention with a beta-blocker, topiramate, or CGRP-targeted therapy is added once attacks are frequent or disabling.
- Hypoglycemia in adults
Hypoglycemia is a plasma glucose below 70 mg/dL, most often a complication of insulin or sulfonylurea therapy for diabetes, and in a person without diabetes it requires a Whipple triad-based evaluation for insulinoma or another endogenous cause. An alert patient is treated with 15 to 20 g of fast-acting oral carbohydrate, while a patient unable to swallow safely receives intramuscular glucagon 1 mg or intravenous dextrose 50% 25 g.
- Essential hypertension
Essential (primary) hypertension is chronically elevated blood pressure without an identifiable secondary cause, the overwhelming majority of hypertension. It is a leading modifiable driver of stroke, heart failure, and kidney disease, and management combines lifestyle change with staged pharmacotherapy to a target usually below 130/80 mmHg.